new weight loss drug glp-1 Patent and Innovation Trends in and Drugs (2020–2025) Swiss Re says GLP-1 drugs

The anti-obesity medication (AOM) marketplace is rapidly expanding, with analysts estimating it to be worth $150 billion by 2032, fueled by the increasing demand for effective weight management (e.g., 15-25% weight loss) and metabolic health solutions

Diabetes 44 , 11261131 (1995)

Research shows that the sedative effect is due to the organic materials (e.g xanthohumols, myrcenols and alpha and beta acid derivates) which are removed to negligible levels during the supercritical CO2 extraction to develop Amarasate

On the other, specialists such as Dr Shalini hold that the evidence has not caught up with the practice

The most important step is a comprehensive, evidence-based consultation with a weight loss specialist

Reny, Genve (Mdecine interne gnrale)